Is a dapagliflozin/metformin fixed‑dose combination of 5 mg dapagliflozin and 1000 mg metformin taken orally twice daily an appropriate dosage for an adult with type 2 diabetes and normal renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dapagliflozin/Metformin 5/1000mg PO BID Dosing Assessment

No, dapagliflozin/metformin 5/1000mg PO BID is not the standard recommended dosage for adults with type 2 diabetes and normal renal function. The FDA-approved and guideline-recommended dosing for dapagliflozin is once daily, not twice daily, and the typical therapeutic dose is 10 mg once daily for most indications 1.

Standard Dosing According to FDA Label and Guidelines

Dapagliflozin Dosing

  • For glycemic control in type 2 diabetes: Start with 5 mg once daily, can increase to 10 mg once daily for additional glycemic benefit 1
  • For cardiovascular/renal protection: 10 mg once daily 2, 3
  • Frequency: Once daily administration is standard 1

Metformin Dosing

  • Standard dosing: 500-1000 mg twice daily is appropriate 4, 5
  • Maximum dose: Up to 2000-2550 mg/day divided into 2-3 doses

Why This Specific Combination is Problematic

The 5/1000mg BID regimen you're asking about contains:

  • Dapagliflozin 5 mg twice daily (total 10 mg/day) - non-standard frequency
  • Metformin 1000 mg twice daily (total 2000 mg/day) - appropriate

Key Issues:

  1. Dapagliflozin is designed for once-daily dosing due to its long half-life and sustained pharmacodynamic effect on renal glucose reabsorption 1

  2. While research shows dapagliflozin can be given twice daily with similar 24-hour glucose excretion 6, 7, this is not FDA-approved or guideline-recommended for clinical practice

  3. The cardiovascular and renal outcome trials that established dapagliflozin's benefits all used once-daily dosing (10 mg daily) 2, 3, 2, 8

Correct Dosing Approach

For a patient with type 2 diabetes and normal renal function (eGFR ≥45 mL/min/1.73 m²):

Option 1: Separate medications

  • Dapagliflozin: 10 mg once daily (morning)
  • Metformin: 1000 mg twice daily (with meals)

Option 2: If using fixed-dose combination

  • Available FDC products typically contain dapagliflozin 5 or 10 mg with metformin 500,850, or 1000 mg
  • Dosing: Once or twice daily depending on the specific formulation
  • Standard would be dapagliflozin 10 mg/metformin 1000 mg taken once or twice daily to achieve total daily metformin dose

Renal Function Considerations

With normal renal function (eGFR ≥60 mL/min/1.73 m²):

  • No dose adjustment needed for either medication 4, 5

If eGFR 45-59 mL/min/1.73 m²:

  • Dapagliflozin 10 mg once daily can continue 4
  • Consider reducing metformin to 1000 mg total daily in some patients 5

If eGFR 30-44 mL/min/1.73 m²:

  • Dapagliflozin 10 mg once daily can continue for CV/renal benefits 4
  • Reduce metformin to maximum 1000 mg daily 4, 5

If eGFR <30 mL/min/1.73 m²:

  • Metformin is contraindicated 4, 5
  • Dapagliflozin can continue if eGFR ≥25 for non-glycemic benefits 4, 1

Clinical Pitfalls to Avoid

  1. Don't split dapagliflozin dosing - the once-daily regimen is what demonstrated mortality and morbidity benefits in major trials 2, 3, 8

  2. Don't assume BID dosing improves efficacy - research shows similar 24-hour glucose excretion with once vs. twice daily dosing 6, 7, but clinical outcomes data only support once-daily use

  3. Don't forget to assess volume status before initiating dapagliflozin, especially in elderly patients or those on diuretics 1

  4. Don't use dapagliflozin primarily for glucose lowering in patients with eGFR <45 - it's ineffective for glycemic control but maintains CV/renal benefits 1

Bottom Line

The correct regimen for most patients would be dapagliflozin 10 mg once daily plus metformin 1000 mg twice daily (or appropriate dose based on tolerance and renal function). The twice-daily dosing of dapagliflozin lacks clinical trial support for improved outcomes and deviates from FDA-approved labeling 1.

Related Questions

What is the recommended dosage and titration schedule for dapagliflozin (Gliflozin)?
Can I take Forxiga (dapagliflozin) at 12 noon and Tradjenta Duo (linagliptin + metformin) at 12 noon and 12 midnight?
Can a 52-year-old male with type 2 diabetes who is taking empagliflozin (Jardiance) 10 mg daily and metformin 1000 mg twice daily switch to dapagliflozin (Farxiga), and how should this be done?
Can I give metformin XR (Glumet XR) 500 mg once daily after dinner with dapagliflozin 10 mg after breakfast, and increase metformin XR to 1000 mg (two tablets) after dinner if glucose remains elevated after one month?
Can I switch metformin extended‑release 1 g once daily to Trajenta Duo (linagliptin 2.5 mg + metformin 500 mg) twice daily and continue dapagliflozin 10 mg once daily if my diabetes is not controlled with dapagliflozin (Forxiga) and metformin controlled‑release 1 g once daily?
Why should Ringer's lactate not be used in the first 24 hours after a traumatic brain injury?
Is prednisolone 1% ophthalmic drop appropriate for a 14-year-old female's right eye?
How should hypoglycemia be managed in a patient with traumatic brain injury?
Is CalmAid (containing Silexan [lavender oil] and possibly diphenhydramine) safe to use during pregnancy?
How should I manage a patient with chronic thrombocytosis and a platelet count of 626 × 10⁹/L?
In a 14-year-old female with steroid-responsive right-eye inflammation, what is the appropriate daily dose (drops per day) of prednisolone acetate 1% eye drops and the total duration of therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.